Alendronate treatment for hip osteoarthritis: Prospective randomized 2-year trial

Clinical Rheumatology

Volumn 32, Issue 12, 2013, Pages 1759-1766

  Nishii, Takashi ^a   Tamura, Satoru ^a   Shiomi, Toshiyuki ^a   Yoshikawa, Hideki ^a   Sugano, Nobuhiko ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Alendronate; Hip osteoarthritis; Randomized controlled trial; Structure modifying effects; Symptom modifying effects

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; CALCIUM LACTATE; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 2; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; BONE DENSITY; BONE RADIOGRAPHY; CLINICAL ARTICLE; COMPUTER ASSISTED RADIOGRAPHY; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HIP OSTEOARTHRITIS; HUMAN; JOINT SPACE WIDTH; MALE; MUSCULOSKELETAL SYSTEM PARAMETERS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VISUAL ANALOG SCALE; WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; ALENDRONATE; ARTHROPLASTY, REPLACEMENT, HIP; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM COMPOUNDS; COLLAGEN TYPE I; COLLAGEN TYPE II; DIPHOSPHONATES; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LACTATES; MALE; MIDDLE AGED; OSTEOARTHRITIS, HIP; PAIN; PAIN MEASUREMENT; PEPTIDE FRAGMENTS; PEPTIDES; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84890331904     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2338-8     Document Type: Article

References (33)

1. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S, Hirsch R, Hochberg MC, Hunder GG, Jordan JM, Katz JN, Kremers HM, Wolfe F (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 58:26-35
2. Yoshimura N, Campbell L, Hashimoto T, Kinoshita H, Okayasu T, Wilman C, Coggon D, Croft P, Cooper C (1998) Acetabular dysplasia and hip osteoarthritis in Britain and Japan. Br J Rheumatol 37:1193-1197
3. Della Valle CJ, Mesko NW, Quigley L, Rosenberg AG, Jacobs JJ, Galante JO (2009) Primary total hip arthroplasty with a porous-coated acetabular component. A concise follow-up, at a minimum of 20 years, of previous reports. J Bone Joint Surg Am 91:1130-1135
4. Takatori Y, Ninomiya S, Nakamura S, Morimoto S, Moro T, Nagai I, Mabuchi A (2001) Long-term results of rotational acetabular osteotomy in patients with slight narrowing of the joint space on preoperative radiographic findings. J Orthop Sci 6:137-140
5. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000; 43:1905-1915
6. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P (2008) OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil 16:137-162
7. Bettica P, Cline G, Hart DJ, Meyer J, Spector TD (2002) Evidence for increased bone resorption in patients with progressive knee osteoarthritis: longitudinal results from the Chingford study. Arthritis Rheum 46:3178-3184
8. Burr DB (1998) The importance of subchondral bone in osteoarthrosis. Curr Opin Rheumatol 10:256-262
9. Carbone LD, Nevitt MC, Wildy K, Barrow KD, Harris F, Felson D, Peterfy C, Visser M, Harris TB, Wang BW, Kritchevsky SB (2004) The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum 50:3516-3525
10. Garnero P, Aronstein WS, Cohen SB, Conaghan PG, Cline GA, Christiansen C, Beary JF, Meyer JM, Bingham CO 3rd (2008) Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial. Osteoarthr Cartil 16:660-666
11. Spector TD, Conaghan PG, Buckland-Wright JC, Garnero P, Cline GA, Beary JF, Valent DJ, Meyer JM (2005) Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial. Arthritis Res Ther 7:R625-R633
12. Buckland-Wright JC, Messent EA, Bingham CO 3rd, Ward RJ, Tonkin C (2007) A 2-year longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients. Rheumatology 46:257-264
13. Laslett LL, Doré DA, Quinn SJ, Boon P, Ryan E, Winzenberg TM, Jones G (2012) Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial. Ann Rheum Dis 71:1322-1328
14. Kellgren JH, Lawrence JS (1957) Radiological assessment of osteo-arthrosis. Ann Rheum Dis 16:494-502
15. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW (1988) Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15:1833-1840
16. Rosen HN, Dresner-Pollak R, Moses AC, Rosenblatt M, Zeind AJ, Clemens JD, Greenspan SL (1994) Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover. Calcif Tissue Int 54:26-29
17. Reijman M, Hazes JM, Bierma-Zeinstra SM, Koes BW, Christgau S, Christiansen C, Uitterlinden AG, Pols HA (2004) A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 50:2471-2478
18. Garnero P, Ayral X, Rousseau JC, Christgau S, Sandell LJ, Dougados M, Delmas PD (2002) Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 46:2613-2624
19. Peterfy CG, Ermazi A, Zaim S, Tirman PF, Miaux Y, White D, Kothari M, Lu Y, Fye K, Zhao S, Genant HK (2004) Whole-organ magnetic resonance imaging score (WORMS) of the knee in osteoarthritis. Osteoarthr Cartil 12:177-190
20. Taljanovic MS, Graham AR, Benjamin JB, Gmitro AF, Krupinski EA, Schwartz SA, Hunter TB, Resnick DL (2008) Bone marrow edema pattern in advanced hip osteoarthritis: quantitative assessment with magnetic resonance imaging and correlation with clinical examination, radiographic findings, and histopathology. Skeletal Radiol 37:423-431
21. Roemer FW, Hunter DJ, Winterstein A, Li L, Kim YJ, Cibere J, Mamisch TC, Guermazi A (2011) Hip Osteoarthritis MRI Scoring System (HOAMS): reliability and associations with radiographic and clinical findings. Osteoarthr Cartil 19:946-962
22. Nishii T, Shiomi T, Sakai T, Takao M, Yoshikawa H, Sugano N (2012) Computational measurement of joint space width and structural parameters in normal hips. Arch Orthop Trauma Surg 132:591-598
23. Langford R, McKenna F, Ratcliffe S, Vojtassák J, Richarz U (2006) Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo-controlled trial. Arthritis Rheum 54:1829-1837
24. Hayami T, Pickarski M, Wesolowski GA, McLane J, Bone A, Destefano J, Rodan GA, le Duong T (2004) The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum 50:1193-1206
25. Shirai T, Kobayashi M, Nishitani K, Satake T, Kuroki H, Nakagawa Y, Nakamura T (2011) Chondroprotective effect of alendronate in a rabbit model of osteoarthritis. J Orthop Res 29:1572-1577
26. Van Offel JF, Dombrecht EJ, Bridts CH, Schuerwegh AJ, Ebo DG, Stevens WJ, De Clerck LS (2005) Influence of bisphosphonates on the production of pro-inflammatory cytokines by activated human articular chondrocytes. Cytokine 31:298-304
27. Bingham CO 3rd, Buckland-Wright JC, Garnero P, Cohen SB, Dougados M, Adami S, Clauw DJ, Spector TD, Pelletier JP, Raynauld JP, Strand V, Simon LS, Meyer JM, Cline GA, Beary JF (2006) Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the 2-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 54:3494-3507
28. Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, Bombardier C, Felson D, Hochberg M, van der Heijde D, Dougados M (2005) Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Ann Rheum Dis 64:29-33
29. Nagae M, Hiraga T, Wakabayashi H, Wang L, Iwata K, Yoneda T (2006) Osteoclasts play a part in pain due to the inflammation adjacent to bone. Bone 39:1107-1115
30. Ornetti P, Brandt K, Hellio-Le Graverand MP, Hochberg M, Hunter DJ, Kloppenburg M, Lane N, Maillefert JF, Mazzuca SA, Spector T, Utard-Wlerick G, Vignon E, Dougados M (2009) OARSI-OMERACT definition of relevant radiological progression in hip/knee osteoarthritis. Osteoarthr Cartil 17:856-863
31. van Spil WE, Drossaers-Bakker KW, Lafeber FP (2013) Associations of CTX-II with biochemical markers of bone turnover raise questions on its tissue origin: data from CHECK, a cohort study of early osteoarthritis. Ann Rheum Dis 72:29-36
32. Suka M, Yoshida K (2009) The national burden of musculoskeletal pain in Japan: projections to the year 2055. Clin J Pain 25:313-319
33. Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Taga M, Nakamura T, Kaneda K, Minaguchi H, Inoue T, Morii H, Tomita A, Yamamoto K, Nagata Y, Nakashima M, Orimo H (1999) A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis: The Alendronate Phase III Osteoporosis Treatment Research Group. Osteoporos Int 10:183-192